Morgan Stanley Cuts Alnylam Pharmaceuticals Price Target to $240
Morgan Stanley maintained its Equal-Weight rating on Alnylam Pharmaceuticals while cutting its price target to $240 per share from $300.
Related stories
Procter & Gamble Closes $4 Billion Notes Offering
Procter & Gamble closed a $4 billion notes offering.
M impact | EQUITY | Oct 30, 2026, 08:24 PM UTC
VantageScore CEO Silvio Tavares Steps Down; Anthony Hutchinson Named Interim CEO
M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC
Twilio Reports Third-Quarter 2026 Revenue of $1.56 Billion
Twilio reported revenue of $1.56 billion, up 19.9% year over year. Net income was $161.16 million, compared with $37.25 million a year earlier, and diluted EPS rose to $1 from $0.2
M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC
Ingersoll Rand Reports Third-Quarter 2026 Revenue of $2.06B
Ingersoll Rand reported revenue up 5.6% year over year. Net income was $669.9M and diluted EPS was $1.73, versus $244.1M and $0.61 a year earlier.
M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC
Weyerhaeuser Reports Third-Quarter Revenue of $1.862 Billion
Revenue rose 8.4% to $1.862 billion from $1.717 billion a year earlier, while net income fell to $61 million from $80 million and diluted EPS declined to $0.08 from $0.11.
M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC
Labcorp Reports Third-Quarter Revenue of $3.81 Billion, EPS of $3.22
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% year over year, and net income of $262.8 million, up 0.7%. Diluted EPS rose 3.2% to $3.22; growth reflected or
M impact | EQUITY | Oct 30, 2026, 08:21 PM UTC